Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;73(12):2231-2247.
doi: 10.1007/s00011-024-01960-y. Epub 2024 Oct 26.

IL-1 receptor antagonist: etiological and drug delivery systems overview

Anand Ubhe  1
Affiliations
Review

IL-1 receptor antagonist: etiological and drug delivery systems overview

Anand Ubhe. Inflamm Res. 2024 Dec.

Abstract

Objective: This article is aims to provide an overview of studies reported in the literature to investigate the etiological role of IL-1/IL-1ra in various disease conditions and the different drug delivery systems developed to achieve IL-1ra as a possible therapeutic option.

Methods: Studies reported in PubMed, Google scholar, and other open-source literature related to etiological involvement of IL-1ra in pathophysiological conditions and various drug delivery schemes developed for IL-1ra for its efficacy evaluation as a possible treatment for different disease conditions were surveyed.

Results and conclusions: The pathophysiological conditions involving IL-1/IL-1 ra spanned CNS-related disorders, Diabetes, Cardiac disorders, Ocular disease conditions, Gastrointestinal conditions, Tumor growth & metastasis, and miscellaneous conditions. The drug delivery systems developed for IL-1ra included a commercial drug product, Gene therapy, Antibody fusions, Extended-release delivery systems, and Pegylated-IL-1ra systems.

Keywords: Drug delivery; Etiology; Interleukin-1; Interleukin-1 receptor antagonist.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: Anand Ubhe is an employee of AbbVie and may own AbbVie stock. AbbVie contributed to reviewing, and approval of the final publication.

References

    1. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20–38. - PubMed - DOI
    1. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging. 2010;27:95–115. - PubMed - DOI
    1. Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT 3rd, et al. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthr Cartil OARS Osteoarthr Res Soc. 2012;20:271–8. - DOI
    1. Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a Randomized Clinical Trial. JAMA Ophthalmol. 2013;131:715–23. - PubMed - PMC - DOI
    1. Papathanasiou E, Conti P, Carinci F, Lauritano D, Theoharides TC. IL-1 Superfamily members and periodontal diseases. J Dent Res. 2020;99:1425–34. - PubMed - PMC - DOI

MeSH terms

Substances

LinkOut - more resources